Perifosine induces protective autophagy and upregulation of ATG5 in human chronic myelogenous leukemia cells in vitro

Acta Pharmacologica Sinica

Volumn 33, Issue 4, 2012, Pages 542-550

  Tong, Yin ^a   Liu, Yan Yan ^a   You, Liang Shun ^a   Qian, Wen Bin ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

acute myeloid leukemia; Akt inhibitor; apoptosis; ATG5; autophagy; beclin 1; chronic myeloid leukemia; perifosine

Indexed keywords

AUTOPHAGY PROTEIN 5; BECLIN 1; CASPASE 3; CASPASE 9; CHLOROQUINE; PERIFOSINE; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL DESTRUCTION; CANCER INHIBITION; CANCER RESISTANCE; CELL ASSAY; CELL PROTECTION; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; ELECTRON MICROSCOPY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LEUKEMIA CELL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MAP KINASE KINASE 4; MICROTUBULE-ASSOCIATED PROTEINS; PHOSPHORYLCHOLINE; PROTO-ONCOGENE PROTEINS C-AKT; UP-REGULATION;

EID: 84859578871     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2011.192     Document Type: Article

References (45)

1. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008; 112: 4808-17.
2. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984; 36: 93-9. (Pubitemid 14155374)
3. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210 bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824-30.
4. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105: 2640-53. (Pubitemid 40446252)
5. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-80. (Pubitemid 32743979)
6. Koptyra M, Falinski R, Nowicki MO, Stoklosa T, Majsterek I, Nieborowska- Skorska M, et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 2006; 108: 319-27. (Pubitemid 43990645)
7. Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci PG, et al. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 1994; 13: 764-73 (Pubitemid 24057507)
8. Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, Hölbl A, et al. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood 2011; 117: 3409-20.
9. Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen SC, Zon G, et al. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995; 86: 726-36.
10. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501. (Pubitemid 37328931)
11. Quintás-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009; 113: 1619-30.
12. Ruiter GA, Zerp SF, Bartelink H, van Blitterswijk WJ, Verheij M. Anticancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs 2003; 14: 167-73. (Pubitemid 36269756)
13. Helgason GV, Karvela M, Holyoake TL. Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. Blood 2011; 118: 2035-43.
14. Jamieson CH. Chronic myeloid leukemia stem cells. Hematology Am Soc Hematol Educ Program 2008: 436-42.
15. Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, Müller- Brüsselbach S, et al. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 2005; 19: 1774-82. (Pubitemid 41486155)
16. Vink SR, Schellens JH, van Blitterswijk WJ, Verheij M. Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid. Invest New Drugs 2005; 23: 279-86. (Pubitemid 40980350)
17. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 2008; 11: 32-50.
18. Nyåkern M, Cappellini A, Mantovani I, Martelli AM. Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways. Mol Cancer Ther 2006; 5: 1559-70. (Pubitemid 44070493)
19. Papa V, Tazzari PL, Chiarini F, Cappellini A, Ricci F, Billi AM, et al. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia 2008; 22: 147-60.
20. Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006; 107: 4053-62. (Pubitemid 43726814)
21. Richardson P, Lonial S, Jakubowiak A, Krishnan A, Wolf J, Densmore J, et al. Multi-center phase II study of Perifosine (KRX-0401) alone and in combination with dexamethasone (Dex) for patients with relapsed or relapsed/refractory multiple myeloma (MM): promising activity as combination therapy with manageable toxicity. Blood 2007; 110: 1164.
22. Levy DS, JA Kahana JA, Kumar R. AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. Blood 2009; 113: 1723-29.
23. Yang C, Tong Y, Ni W, Liu J, Xu W, Li L, et al. Inhibition of autophagy induced by overexpression of MDA/Interleukin-24 using a PI3K inhibitor results in significant enhanced antileukmia activity in vivo. Cancer Gene Ther 2010; 17: 109-19.
24. Elrod HA, Lin YD, Yue P, Wang X, Lonial S, Khuri FR, et al. The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Mol Cancer Ther 2007; 6: 2029-38. (Pubitemid 47052493)
25. Rahmani M, Reese E, Dai Y, Bauer C, Payne SG, Dent P, et al. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res 2005; 65: 2422-32. (Pubitemid 40490154)
26. Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. Nat Rev Cancer 2007; 7: 961-7. (Pubitemid 350165856)
27. Qian W, Liu J, Jin J, Ni W, Xu W. Arsenic trioxide induces not only apoptosis but also autophagic cell death in leukemia cell lines via upregulation of Beclin-1. Leuk Res 2007; 31: 329-39. (Pubitemid 46073178)
28. Carew JS, Nawrocki ST, Kahue CN, Zhang H, Yang C, Chung L, et al. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 2007; 110: 313-22. (Pubitemid 47026849)
29. Yu L, Alva A, Su H, Dutt P, Freundt E, Welsh S, et al. Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8. Science 2004; 304: 1500-2. (Pubitemid 38720930)
30. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008; 132: 27-42.
31. Kawauchi K, Ogasawara T, Yasuyama M, Ohkawa S. Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells. Blood Cells Mol Dis 2003; 31: 11-7. (Pubitemid 36805629)
32. Li Z, Tan F, Liewehr DJ, Steinberg SM, Thiele CJ. In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosine. J Natl Cancer Inst 2010; 102: 758-70.
33. Han J, Hou W, Goldstein LA, Lu C, Stolz DB, Yin XM, et al. Involvement of protective autophagy in TRAIL resistance of apoptosis-defective tumor cells. J Biol Chem 2008; 283: 19665-77.
34. Ertmer A, Huber V, Gilch S, Yoshimori T, Erfle V, Duyster J, et al. The anticancer drug imatinib induces cellular autophagy. Leukemia 2007; 21: 936-42. (Pubitemid 46672069)
35. Kamitsuji Y, Kuroda J, Kimura S, Toyokuni S, Watanabe K, Ashihara E, et al. The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias. Cell Death Differ 2008; 15: 1712-22.
36. Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009; 119: 1109-23.
37. Fu L, Kim YA, Wang X, Wu X, Yue P, Lonial S, et al. Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res 2009; 69: 8967-76.
38. Degtyarev M, De Mazière A, Orr C, Lin J, Lee BB, Tien JY, et al. Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. J Cell Biol 2008; 183: 101-16.
39. Chu CT, Zhu J, Dagda R. Beclin 1-independent pathway of damage-induced mitophagy and autophagic stress: implications for neurodegeneration and cell death. Autophagy 2007; 3: 663-6. (Pubitemid 350060074)
40. Scarlatti F, Maffei R, Beau I, Ghidoni R, Codogno P. Non-canonical autophagy: an exception or an underestimated form of autophagy? Autophagy 2008; 4: 1083-5.
41. Scarlatti F, Maffei R, Beau I, Codogno P, Ghidoni R. Role of noncanonical Beclin 1-independent autophagy in cell death induced by resveratrol in human breast cancer cells. Cell Death Differ 2008; 15: 1318-29. (Pubitemid 351984760)
42. Smith DM, Patel S, Raffoul F, Haller E, Mills GB, Nanjundan M. Arsenic trioxide induces a beclin-1-independent autophagic pathway via modulation of SnoN/SkiL expression in ovarian carcinoma cells. Cell Death Differ 2010; 17: 1867-81.
43. Nishida Y, Arakawa S, Fujitani K, Yamaguchi H, Mizuta T, Kanaseki T, et al. Discovery of Atg5/Atg7-independent alternative macroautophagy. Nature 2009; 461: 654-8.
44. Gao P, Bauvy C, Souquère S, Tonelli G, Liu L, Zhu Y, et al. The Bcl-2 homology domain 3 mimetic gossypol induces both Beclin 1-dependent and Beclin 1-independent cytoprotective autophagy in cancer cells. J Biol Chem 2010; 285: 25570-81.
45. Xia HG, Zhang L, Chen G, Zhang T, Liu J, Jin M, et al. Control of basal autophagy by calpain1 mediated cleavage of ATG5. Autophagy 2010; 6: 61-6.